{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:10:22Z","timestamp":1790871022479,"version":"4.1.0"},"reference-count":107,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Liver Dis"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>Metabolic and alcohol-related liver disease (MetALD) is a subcategory of steatotic liver disease (SLD) characterized by the coexistence of cardiometabolic risk factors and elevated alcohol intake. The global prevalence of MetALD is estimated to be 2 to 5%, but this is likely underestimated due to self-reporting biases. In real-world settings, fluctuations in alcohol intake mean that many patients with SLD may be classified as having MetALD at some point during their disease. Although MetALD is relatively common, only a minority of patients with the disorder progress to advanced chronic liver disease. Genetic factors modulate disease initiation and progression, with risk variants in PNPLA3, HSD17B13, and TM6SF2 being particularly relevant. Polygenic risk scores incorporating these and other variants have demonstrated a potential for identifying at-risk individuals. This review comprehensively examines MetALD, covering its natural history, genetic underpinnings, clinical outcomes, the predictive potential of genetic risk scores, and future therapeutic avenues involving gene silencing.<\/jats:p>","DOI":"10.1055\/a-2630-0952","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T18:43:32Z","timestamp":1749494612000},"page":"269-282","source":"Crossref","is-referenced-by-count":9,"title":["MetALD: Genetic Factors and Clinical Outcomes"],"prefix":"10.1055","volume":"45","author":[{"given":"Mads","family":"Israelsen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Centre for Liver Research, Odense University Hospital, Odense, Denmark"},{"name":"Institute of Clinical Research, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Tr\u00e9po","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, H\u00f4pital Universitaire de Bruxelles, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium"},{"name":"Laboratory of Experimental Gastroenterology, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Krag","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Centre for Liver Research, Odense University Hospital, Odense, Denmark"},{"name":"Institute of Clinical Research, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Stender","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"issue":"02","key":"ref1","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"H Devarbhavi","year":"2023","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(24)01811-7","article-title":"Steatotic liver disease","volume":"404","author":"M Israelsen","year":"2024","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","article-title":"The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality","volume":"399","author":"T H Karlsen","year":"2022","journal-title":"Lancet"},{"issue":"04","key":"ref4","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1053\/j.gastro.2020.05.007","article-title":"Decline in annual mortality of hepatitis C virus-related hepatocellular carcinoma in the United States, from 2009 to 2018","volume":"159","author":"D Kim","year":"2020","journal-title":"Gastroenterology"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41575-024-01022-y","article-title":"The steatotic liver disease burden paradox: unravelling the key role of alcohol","volume":"22","author":"N Torp","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Z Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10","key":"ref8","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/apt.17958","article-title":"Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population","volume":"59","author":"C V Schneider","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"101750","DOI":"10.1016\/j.aohep.2024.101750","article-title":"Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases","volume":"30","author":"Y Xiao","year":"2025","journal-title":"Ann Hepatol"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"e70087","DOI":"10.1002\/mco2.70087","article-title":"Prognostic and predictive effects of new steatotic liver disease nomenclatures: a large population-based study","volume":"6","author":"H Zeng","year":"2025","journal-title":"MedComm"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/apt.18015","article-title":"Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality","volume":"60","author":"N Tamaki","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/gutjnl-2023-331003","article-title":"Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease","volume":"73","author":"H H Lee","year":"2024","journal-title":"Gut"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"102292","DOI":"10.1016\/j.eclinm.2023.102292","article-title":"Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study","volume":"65","author":"J H Moon","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"02","key":"ref14","doi-asserted-by":"crossref","first-page":"410","DOI":"10.14309\/ajg.0000000000002920","article-title":"Liver cancer risk across metabolic dysfunction-associated steatotic liver disease and\/or alcohol: a nationwide study","volume":"120","author":"B Yun","year":"2025","journal-title":"Am J Gastroenterol"},{"issue":"04","key":"ref15","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1159\/000535943","article-title":"Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatotic liver disease with increased alcohol intake increase the risk of developing hepatocellular carcinoma and incident or decompensated cirrhosis: a Korean nationwide study","volume":"13","author":"G A Kim","year":"2023","journal-title":"Liver Cancer"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1111\/apt.18286","article-title":"Metabolic dysfunction-associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: a nationwide cohort study","volume":"60","author":"Y Park","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"06","key":"ref17","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/HEP.0000000000000664","article-title":"Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings","volume":"79","author":"C M Lee","year":"2024","journal-title":"Hepatology"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"101172","DOI":"10.1016\/j.jhepr.2024.101172","article-title":"ALT levels, alcohol use, and metabolic risk factors have prognostic relevance for liver-related outcomes in the general population","volume":"6","author":"V M\u00e4nnist\u00f6","year":"2024","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"03","key":"ref20","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/HEP.0000000000000604","article-title":"National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature","volume":"79","author":"B P Lee","year":"2024","journal-title":"Hepatology"},{"issue":"10","key":"ref21","doi-asserted-by":"crossref","first-page":"101127","DOI":"10.1016\/j.jhepr.2024.101127","article-title":"Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score","volume":"6","author":"P Sripongpun","year":"2024","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"11","key":"ref22","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1111\/liv.15695","article-title":"Exploring the landscape of steatotic liver disease in the general US population","volume":"43","author":"S Ciardullo","year":"2023","journal-title":"Liver Int"},{"issue":"05","key":"ref24","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.cgh.2024.01.006","article-title":"Misclassified alcohol-related liver disease is common in presumed metabolic dysfunction-associated steatotic liver disease and highly increases risk for future cirrhosis","volume":"22","author":"P Nasr","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"04","key":"ref25","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2022.04.040","article-title":"Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease","volume":"77","author":"K Staufer","year":"2022","journal-title":"J Hepatol"},{"issue":"07","key":"ref26","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.dld.2024.01.195","article-title":"You can't handle the truth! Comparing serum phosphatidylethanol to self-reported alcohol intake in chronic liver disease patients","volume":"56","author":"K Scholten","year":"2024","journal-title":"Dig Liver Dis"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S2468-1253(24)00427-8","article-title":"Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD","volume":"10","author":"A Krag","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"06","key":"ref28","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/apt.18165","article-title":"Prevalence and prognosis of patients with MASLD-related cirrhosis after an ICU hospitalization in France: a single-centre prospective study","volume":"60","author":"P Sultanik","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"01","key":"ref29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1034\/j.1600-0676.2003.01804.x","article-title":"Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence","volume":"23","author":"F Pessione","year":"2003","journal-title":"Liver Int"},{"issue":"01","key":"ref30","doi-asserted-by":"crossref","first-page":"101200","DOI":"10.1016\/j.jhepr.2024.101200","article-title":"Quantification of alcohol intake in patients with steatotic liver disease and excessive alcohol intake","volume":"7","author":"E D Hansen","year":"2024","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"04","key":"ref31","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"G Lassailly","year":"2020","journal-title":"Gastroenterology"},{"issue":"05","key":"ref32","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41588-024-01720-y","article-title":"Integrative common and rare variant analyses provide insights into the genetic architecture of liver cirrhosis","volume":"56","author":"J Ghouse","year":"2024","journal-title":"Nat Genet"},{"issue":"10","key":"ref33","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S2468-1253(23)00206-6","article-title":"MetALD: new opportunities to understand the role of alcohol in steatotic liver disease","volume":"8","author":"M Israelsen","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"ref34","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s41588-022-01199-5","article-title":"Multiomics study of nonalcoholic fatty liver disease","volume":"54","author":"G Sveinbjornsson","year":"2022","journal-title":"Nat Genet"},{"issue":"12","key":"ref35","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"N S Abul-Husn","year":"2018","journal-title":"N Engl J Med"},{"issue":"01","key":"ref36","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhep.2022.08.030","article-title":"Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease","volume":"78","author":"F \u00c5berg","year":"2023","journal-title":"J Hepatol"},{"issue":"01","key":"ref37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.gtc.2019.09.001","article-title":"Genetic risk factors and disease modifiers of nonalcoholic steatohepatitis","volume":"49","author":"J Kozlitina","year":"2020","journal-title":"Gastroenterol Clin North Am"},{"issue":"01","key":"ref38","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1470-2045(21)00603-3","article-title":"Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study","volume":"23","author":"E Tr\u00e9po","year":"2022","journal-title":"Lancet Oncol"},{"issue":"12","key":"ref39","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"S Romeo","year":"2008","journal-title":"Nat Genet"},{"issue":"02","key":"ref40","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2016.03.011","article-title":"PNPLA3 gene in liver diseases","volume":"65","author":"E Tr\u00e9po","year":"2016","journal-title":"J Hepatol"},{"issue":"01","key":"ref41","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/hep.27242","article-title":"Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis","volume":"61","author":"E Smagris","year":"2015","journal-title":"Hepatology"},{"issue":"10","key":"ref42","doi-asserted-by":"crossref","first-page":"e2234221","DOI":"10.1001\/jamanetworkopen.2022.34221","article-title":"Synergistic associations of PNPLA3 I148M variant, alcohol intake, and obesity with risk of cirrhosis, hepatocellular carcinoma, and mortality","volume":"5","author":"H S Kim","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"03","key":"ref43","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/hep.31032","article-title":"Patatin-like phospholipase domain-containing protein 3 I148M and liver fat and fibrosis scores predict liver disease mortality in the U.S. population","volume":"71","author":"A Unalp-Arida","year":"2020","journal-title":"Hepatology"},{"issue":"09","key":"ref44","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1111\/liv.15629","article-title":"Genetic risk of fatty liver disease and mortality in the general population: a Mendelian randomization study","volume":"43","author":"H Gellert-Kristensen","year":"2023","journal-title":"Liver Int"},{"issue":"03","key":"ref45","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/hep.31113","article-title":"PNPLA3 genotype and risk of liver and all-cause mortality","volume":"71","author":"S Stender","year":"2020","journal-title":"Hepatology"},{"issue":"01","key":"ref46","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/21623945.2019.1607423","article-title":"PNPLA3-I148M: a problem of plenty in non-alcoholic fatty liver disease","volume":"8","author":"S Basu Ray","year":"2019","journal-title":"Adipocyte"},{"issue":"05","key":"ref47","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jhep.2024.10.048","article-title":"PNPLA3(148M) is a gain-of-function mutation that promotes hepatic steatosis by inhibiting ATGL-mediated triglyceride hydrolysis","volume":"82","author":"Y Wang","year":"2025","journal-title":"J Hepatol"},{"issue":"20","key":"ref48","doi-asserted-by":"crossref","first-page":"10659","DOI":"10.1074\/jbc.M116.719955","article-title":"Inactivation of Tm6sf2, a gene defective in fatty liver disease, impairs lipidation but not secretion of very low density lipoproteins","volume":"291","author":"E Smagris","year":"2016","journal-title":"J Biol Chem"},{"issue":"03","key":"ref49","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jcmgh.2021.12.008","article-title":"Hepatic TM6SF2 is required for lipidation of VLDL in a pre-Golgi compartment in mice and rats","volume":"13","author":"F Luo","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"04","key":"ref50","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ng.2926","article-title":"Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk","volume":"46","author":"O L Holmen","year":"2014","journal-title":"Nat Genet"},{"issue":"02","key":"ref51","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/hep.27490","article-title":"Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease","volume":"61","author":"P Dongiovanni","year":"2015","journal-title":"Hepatology"},{"issue":"02","key":"ref52","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbrc.2008.03.063","article-title":"17beta-hydroxysteroid dehydrogenase type 13 is a liver-specific lipid droplet-associated protein","volume":"370","author":"Y Horiguchi","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"issue":"04","key":"ref53","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/liv.14411","article-title":"HSD17B13 as a promising therapeutic target against chronic liver disease","volume":"40","author":"S Stender","year":"2020","journal-title":"Liver Int"},{"issue":"19","key":"ref54","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1056\/NEJMc1804027","article-title":"HSD17B13 and chronic liver disease in Blacks and Hispanics","volume":"379","author":"J Kozlitina","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"ref55","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ng.3417","article-title":"A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis","volume":"47","author":"S Buch","year":"2015","journal-title":"Nat Genet"},{"issue":"04","key":"ref56","doi-asserted-by":"crossref","first-page":"e1009503","DOI":"10.1371\/journal.pgen.1009503","article-title":"Correction: a missense variant in mitochondrial amidoxime reducing component 1 gene and protection against liver disease","volume":"17","author":"C A Emdin","year":"2021","journal-title":"PLoS Genet"},{"issue":"05","key":"ref57","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1053\/j.gastro.2020.12.023","article-title":"Exome-wide association study on alanine aminotransferase identifies sequence variants in the GPAM and APOE associated with fatty liver disease","volume":"160","author":"O Jamialahmadi","year":"2021","journal-title":"Gastroenterology"},{"issue":"01","key":"ref58","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhep.2020.08.027","article-title":"rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: a meta-analysis","volume":"74","author":"K Teo","year":"2021","journal-title":"J Hepatol"},{"issue":"04","key":"ref59","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1056\/NEJMoa2117872","article-title":"Germline mutations in CIDEB and protection against liver disease","volume":"387","author":"N Verweij","year":"2022","journal-title":"N Engl J Med"},{"issue":"05","key":"ref60","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00439-011-1116-4","article-title":"Strong protective effect of the aldehyde dehydrogenase gene (ALDH2) 504lys (*2) allele against alcoholism and alcohol-induced medical diseases in Asians","volume":"131","author":"D Li","year":"2012","journal-title":"Hum Genet"},{"issue":"03","key":"ref61","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/j.gastro.2020.05.054","article-title":"ADH1B\u22172 is associated with reduced severity of nonalcoholic fatty liver disease in adults, independent of alcohol consumption","volume":"159","author":"E Vilar-Gomez","year":"2020","journal-title":"Gastroenterology"},{"issue":"05","key":"ref62","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1158\/1055-9965.EPI-24-1296","article-title":"ALDH2 deficiency and alcohol intake in the United States: opportunity for precision cancer prevention","volume":"34","author":"D Forman","year":"2025","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"08","key":"ref63","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/carcin\/19.8.1383","article-title":"Alcohol-related cancers and aldehyde dehydrogenase-2 in Japanese alcoholics","volume":"19","author":"A Yokoyama","year":"1998","journal-title":"Carcinogenesis"},{"issue":"02","key":"ref64","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jhep.2022.03.033","article-title":"EASL clinical practice guidelines on haemochromatosis","volume":"77","author":"European Association for the Study of the Liver","year":"2022","journal-title":"J Hepatol"},{"issue":"03","key":"ref65","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1053\/j.gastro.2019.05.013","article-title":"Liver fibrosis and metabolic alterations in adults with alpha-1-antitrypsin deficiency caused by the Pi*ZZ mutation","volume":"157","author":"K Hamesch","year":"2019","journal-title":"Gastroenterology"},{"issue":"04","key":"ref66","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jhep.2021.11.022","article-title":"Alpha-1 antitrypsin deficiency: a re-surfacing adult liver disorder","volume":"76","author":"M Fromme","year":"2022","journal-title":"J Hepatol"},{"issue":"03","key":"ref67","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ajhg.2012.01.018","article-title":"Syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia caused by mutations in SLC30A10, a manganese transporter in man","volume":"90","author":"K Tuschl","year":"2012","journal-title":"Am J Hum Genet"},{"issue":"03","key":"ref68","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ajhg.2012.01.017","article-title":"Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease","volume":"90","author":"M Quadri","year":"2012","journal-title":"Am J Hum Genet"},{"issue":"01","key":"ref69","doi-asserted-by":"crossref","first-page":"4571","DOI":"10.1038\/s41467-021-24563-1","article-title":"GWAS of serum ALT and AST reveals an association of SLC30A10 Thr95Ile with hypermanganesemia symptoms","volume":"12","author":"L D Ward","year":"2021","journal-title":"Nat Commun"},{"issue":"03","key":"ref70","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12072-022-10331-w","article-title":"A rare genetic variant in the manganese transporter SLC30A10 and elevated liver enzymes in the general population","volume":"16","author":"A S Seidelin","year":"2022","journal-title":"Hepatol Int"},{"issue":"03","key":"ref71","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S2468-1253(23)00443-0","article-title":"Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study","volume":"9","author":"M Israelsen","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"05","key":"ref72","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jhep.2024.05.042","article-title":"Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort","volume":"81","author":"J H Oh","year":"2024","journal-title":"J Hepatol"},{"issue":"06","key":"ref73","first-page":"e0718","article-title":"Noninvasive pathway for stratifying fibrosis in suspected metabolic dysfunction and alcohol-associated liver disease (MetALD)","volume":"9","author":"L A D\u00edaz","year":"2025","journal-title":"Hepatol Commun"},{"issue":"06","key":"ref74","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/add.13757","article-title":"The relationship between different dimensions of alcohol use and the burden of disease-an update","volume":"112","author":"J Rehm","year":"2017","journal-title":"Addiction"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(18)30134-X","article-title":"Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599\u2008912 current drinkers in 83 prospective studies","volume":"391","author":"A M Wood","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"ref76","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1111\/jgh.16726","article-title":"Mortality outcomes in individuals with MASLD versus MASLD and increased alcohol intake","volume":"39","author":"M B Aboona","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"issue":"08","key":"ref78","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/liv.15939","article-title":"Impact of MASLD and MetALD on clinical outcomes: a meta-analysis of preliminary evidence","volume":"44","author":"S Ciardullo","year":"2024","journal-title":"Liver Int"},{"issue":"01","key":"ref79","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/hep.510250120","article-title":"Excess weight risk factor for alcoholic liver disease","volume":"25","author":"S Naveau","year":"1997","journal-title":"Hepatology"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"c1240","DOI":"10.1136\/bmj.c1240","article-title":"Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies","volume":"340","author":"C L Hart","year":"2010","journal-title":"BMJ"},{"issue":"07","key":"ref81","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/liv.14830","article-title":"Interaction between metabolic syndrome and alcohol consumption, risk factors of liver fibrosis: a population-based study","volume":"41","author":"E Pose","year":"2021","journal-title":"Liver Int"},{"issue":"06","key":"ref82","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1002\/hep.29631","article-title":"Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population","volume":"67","author":"F \u00c5berg","year":"2018","journal-title":"Hepatology"},{"issue":"04","key":"ref83","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.cgh.2019.06.036","article-title":"Combined effects of alcohol and metabolic disorders in patients with chronic liver disease","volume":"18","author":"F \u00c5berg","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"02","key":"ref84","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/jgh.14770","article-title":"Genetic and lifestyle risk factors for advanced liver disease among men and women","volume":"35","author":"P Sahlman","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"issue":"08","key":"ref85","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.cgh.2020.11.038","article-title":"Metabolic and genetic risk factors are the strongest predictors of severity of alcohol-related liver fibrosis","volume":"20","author":"M Israelsen","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"02","key":"ref86","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2021.10.005","article-title":"A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers","volume":"76","author":"J B Whitfield","year":"2022","journal-title":"J Hepatol"},{"issue":"01","key":"ref87","doi-asserted-by":"crossref","first-page":"e16211","DOI":"10.1111\/liv.16211","article-title":"PNPLA3 in alcohol-related liver disease","volume":"45","author":"C Galvanin","year":"2025","journal-title":"Liver Int"},{"issue":"06","key":"ref88","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jhep.2020.02.020","article-title":"Update on NAFLD genetics: from new variants to the clinic","volume":"72","author":"E Tr\u00e9po","year":"2020","journal-title":"J Hepatol"},{"issue":"03","key":"ref89","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.cgh.2021.05.056","article-title":"A polygenic risk score to refine risk stratification and prediction for severe liver disease by clinical fibrosis scores","volume":"20","author":"A De Vincentis","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"04","key":"ref90","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jhep.2020.11.024","article-title":"Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores","volume":"74","author":"C Bianco","year":"2021","journal-title":"J Hepatol"},{"issue":"03","key":"ref91","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/hep.31238","article-title":"Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population","volume":"72","author":"H Gellert-Kristensen","year":"2020","journal-title":"Hepatology"},{"issue":"06","key":"ref92","first-page":"e0431","article-title":"A polygenic risk score for alcohol-associated cirrhosis among heavy drinkers with European ancestry","volume":"8","author":"T H Schwantes-An","year":"2024","journal-title":"Hepatol Commun"},{"issue":"03","key":"ref93","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2022.11.003","article-title":"Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis","volume":"78","author":"P Nahon","year":"2023","journal-title":"J Hepatol"},{"issue":"02","key":"ref94","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jhep.2022.02.022","article-title":"Performance of routine risk scores for predicting cirrhosis-related morbidity in the community","volume":"77","author":"H Innes","year":"2022","journal-title":"J Hepatol"},{"issue":"01","key":"ref95","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cmet.2019.12.002","article-title":"Leveraging human genetics to identify potential new treatments for fatty liver disease","volume":"31","author":"S Romeo","year":"2020","journal-title":"Cell Metab"},{"issue":"01","key":"ref96","doi-asserted-by":"crossref","first-page":"101198","DOI":"10.1016\/j.omtm.2024.101198","article-title":"A gene silencing-based approach to tackle fatty liver disease","volume":"32","author":"P Strnad","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"04","key":"ref97","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2022.11.025","article-title":"A phase I\/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis","volume":"78","author":"L Y Mak","year":"2023","journal-title":"J Hepatol"},{"issue":"12","key":"ref98","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/s41575-023-00822-y","article-title":"The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease","volume":"20","author":"L A D\u00edaz","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"03","key":"ref99","doi-asserted-by":"crossref","first-page":"890","DOI":"10.3390\/jcm11030890","article-title":"Effects of moderate alcohol consumption in non-alcoholic fatty liver disease","volume":"11","author":"P Lemmer","year":"2022","journal-title":"J Clin Med"},{"issue":"05","key":"ref100","doi-asserted-by":"crossref","first-page":"100325","DOI":"10.1016\/j.jhepr.2021.100325","article-title":"Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication","volume":"3","author":"M Israelsen","year":"2021","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"10","key":"ref101","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1530\/EC-19-0317","article-title":"Gluco-metabolic effects of oral and intravenous alcohol administration in men","volume":"8","author":"A R Lanng","year":"2019","journal-title":"Endocr Connect"},{"issue":"04","key":"ref102","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jhep.2024.11.028","article-title":"Metabolic dysfunction and alcohol-related liver disease (MetALD): position statement by an expert panel on alcohol-related liver disease","volume":"82","author":"J P Arab","year":"2024","journal-title":"J Hepatol"},{"issue":"06","key":"ref104","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jhep.2024.06.036","article-title":"Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease","volume":"81","author":"D Marti-Aguado","year":"2024","journal-title":"J Hepatol"},{"issue":"06","key":"ref105","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1097\/HEP.0000000000000885","article-title":"Non-invasive tests for alcohol-associated liver disease","volume":"80","author":"M Israelsen","year":"2024","journal-title":"Hepatology"},{"issue":"06","key":"ref106","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/apt.18506","article-title":"Head-to-head comparison between phosphatidylethanol versus indirect alcohol biomarkers for diagnosis of MetALD versus MASLD: a prospective study","volume":"61","author":"F Tavaglione","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"issue":"06","key":"ref107","doi-asserted-by":"crossref","first-page":"E162","DOI":"10.1097\/HEP.0000000000001266","article-title":"Letter to the editor: alcohol a confounding factor in the assessment of resmetirom therapy","volume":"81","author":"A Krag","year":"2025","journal-title":"Hepatology"},{"issue":"06","key":"ref108","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"S A Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"09","key":"ref109","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41575-024-00936-x","article-title":"Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel consensus statement","volume":"21","author":"B P Lee","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"155800","DOI":"10.1016\/j.metabol.2024.155800","article-title":"Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: a community-dwelling cohort study with 20-year follow-up","volume":"153","author":"H J Choe","year":"2024","journal-title":"Metabolism"},{"issue":"06","key":"ref112","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S2468-1253(23)00010-9","article-title":"Rifaximin-\u03b1 for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"8","author":"M Israelsen","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"03","key":"ref113","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/hep.30864","article-title":"Risks of light and moderate alcohol use in fatty liver disease: follow-up of population cohorts","volume":"71","author":"F \u00c5berg","year":"2020","journal-title":"Hepatology"}],"container-title":["Seminars in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2630-0952.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:46:18Z","timestamp":1757544378000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2630-0952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":107,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2025,9,10]]},"published-print":{"date-parts":[[2025,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2630-0952","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0272-8087","1098-8971"],"issn-type":[{"value":"0272-8087","type":"print"},{"value":"1098-8971","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6,9]]},"published":{"date-parts":[[2025,6,9]]}}}